Cargando…

Cross-sectional analysis of pharmaceutical payments to Japanese board-certified gastroenterologists between 2016 and 2019

OBJECTIVES: Limited evidence is available regarding the financial relationships between gastroenterologists and pharmaceutical companies in Japan. This study analysed the magnitude, prevalence and trends of personal payments made by major pharmaceutical companies to board-certified gastroenterologis...

Descripción completa

Detalles Bibliográficos
Autores principales:	Murayama, Anju, Kamamoto, Sae, Kawashima, Moe, Saito, Hiroaki, Yamashita, Erika, Tanimoto, Tetsuya, Ozaki, Akihiko
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2023
Materias:	Ethics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10124293/ https://www.ncbi.nlm.nih.gov/pubmed/37072354 http://dx.doi.org/10.1136/bmjopen-2022-068237

Ejemplares similares

Pharmaceutical payments to Japanese certified hematologists: a retrospective analysis of personal payments from pharmaceutical companies between 2016 and 2019
por: Kusumi, Eiji, et al.
Publicado: (2022)

Pharmaceutical Payments to Japanese Board‐Certified Head and Neck Surgeons Between 2016 and 2019
por: Murayama, Anju, et al.
Publicado: (2023)

Pharmaceutical payments to Japanese board-certified dermatologists: a 4-year retrospective analysis of personal payments from pharmaceutical companies between 2016 and 2019
por: Murayama, Anju, et al.
Publicado: (2023)

Pharmaceutical Payments to Japanese Board-Certified Infectious Disease Specialists: A Four-Year Retrospective Analysis of Payments from 92 Pharmaceutical Companies between 2016 and 2019
por: Murayama, Anju, et al.
Publicado: (2022)

Pharmaceutical payments to certified oncology specialists in Japan in 2016: a retrospective observational cross-sectional analysis
por: Ozaki, Akihiko, et al.
Publicado: (2019)

The Trend in Industry Payments During the COVID-19 Pandemic Among Gastroenterologists and Hepatologists in the United States
por: Murayama, Anju, et al.
Publicado: (2022)

Nature and Trends in Personal Payments Made to the Respiratory Physicians by Pharmaceutical Companies in Japan between 2016 and 2019
por: Murayama, Anju, et al.
Publicado: (2022)

Trends in Industry Payments to Diabetologists and Endocrinologists in the United States During the COVID-19 Pandemic
por: Murayama, Anju, et al.
Publicado: (2022)

Research and Nonresearch Industry Payments for COVID-19 mRNA Vaccines in the United States
por: Murayama, Anju, et al.
Publicado: (2023)

Industry payments to allergists and clinical immunologists in the United States during the coronavirus disease 2019 pandemic
por: Murayama, Anju, et al.
Publicado: (2022)

Trend in industry payments to infectious disease physicians in the United States: a seven-year analysis of nonresearch payments from the Open Payments Database between 2014 and 2020
por: Murayama, Anju, et al.
Publicado: (2022)

Assessment of Financial Relationships Between Otorhinolaryngologists and Pharmaceutical Companies in Japan Between 2016 and 2019
por: Kamamoto, Sae, et al.
Publicado: (2023)

Industry Payments During the COVID-19 Pandemic to Cardiologists in the United States
por: Murayama, Anju, et al.
Publicado: (2023)

Pharmaceutical company payments to the authors of the Japanese dementia clinical practice guidelines in 2016
por: Shimada, Yuki, et al.
Publicado: (2019)

Pharmaceutical company payments to dermatology Clinical Practice Guideline authors in Japan
por: Murayama, Anju, et al.
Publicado: (2020)

Payments From Pharmaceutical Companies to Authors Involved in the Valsartan Scandal in Japan
por: Sawano, Toyoaki, et al.
Publicado: (2019)

Pharmaceutical company payments to authors of the Japanese guidelines for the management of hypertension
por: Senoo, Yuki, et al.
Publicado: (2021)

Evaluation of Financial Conflicts of Interest and Quality of Evidence Underlying the American Diabetes Association Clinical Practice Guidelines: The Standards of Medical Care in Diabetes, 2021
por: Shigeta, Haruki, et al.
Publicado: (2023)

Evaluation of Pharmaceutical Company Payments and Conflict of Interest Disclosures Among Oncology Clinical Practice Guideline Authors in Japan
por: Saito, Hiroaki, et al.
Publicado: (2019)

Coronavirus disease 2019 experts appearing on Japanese television: their characteristics and financial conflicts of interest with pharmaceutical companies
por: Murayama, Anju, et al.
Publicado: (2021)

How Do Institutional Conflicts of Interest Between Pharmaceutical Companies and the Healthcare Sector Become Corrupt? A Case Study of Scholarship Donations Between Department of Clinical Anesthesiology, Mie University, and Ono Pharmaceutical in Japan
por: Ozaki, Akihiko, et al.
Publicado: (2022)

The Sun Is Still Shining: Nature of Industry Payments to Transplant Surgeons From 2014 to 2019
por: Lombardi, Conner V., et al.
Publicado: (2022)

Institutional review boards: Challenges and opportunities
por: Ghooi, Ravindra B.
Publicado: (2014)

Ethical issues in access to and delivery of emergency department care in an era of changing reimbursement and novel payment models
por: Kraus, Chadd K., et al.
Publicado: (2020)

Are institutional review boards prepared for active continuing review?
por: Shetty, Yashashri C., et al.
Publicado: (2014)

Observational study of financial and non-financial conflicts of interest among the Japanese government advisory board members concerning coronavirus disease 2019
por: Mamada, Hanano, et al.
Publicado: (2023)

Interactions between Australian cancer physicians and the pharmaceutical industry: a qualitative study
por: Pokorny, Adrian M J, et al.
Publicado: (2023)

The Ethics of Itemised Payment for Clinical Research Procedures
por: Evans, H. M., et al.
Publicado: (1993)

Measuring clinical trial transparency: an empirical analysis of newly approved drugs and large pharmaceutical companies
por: Miller, Jennifer E, et al.
Publicado: (2017)

Awareness and Perceptions among Members of a Japanese Cancer Patient Advocacy Group Concerning the Financial Relationships between the Pharmaceutical Industry and Physicians
por: Murayama, Anju, et al.
Publicado: (2022)

Assessment of Pharmaceutical Company and Device Manufacturer Payments to Gastroenterologists and Their Participation in Clinical Practice Guideline Panels
por: Nusrat, Salman, et al.
Publicado: (2018)

Pharmaceutical industry funding of events for healthcare professionals on non-vitamin K oral anticoagulants in Australia: an observational study
por: Behdarvand, Behrad, et al.
Publicado: (2019)

‘Lines in the sand’: an Australian qualitative study of patient group practices to promote independence from pharmaceutical industry funders
por: Parker, Lisa, et al.
Publicado: (2021)

When are clinical trials beneficial for study patients and future patients? A factorial vignette-based survey of institutional review board members
por: Mhaskar, Rahul, et al.
Publicado: (2016)

2543: Participatory development of a CTSA-wide Community Advisory Board: Enhancing community engagement at the Michigan Institute for Clinical & Health Research
por: Delva, Jorge, et al.
Publicado: (2018)

How do community advisory boards fulfil their ethical role in HIV clinical trials? A protocol for a systematic review of qualitative evidence
por: Pancras, Godwin, et al.
Publicado: (2020)

Moving towards a better path? A mixed-method examination of China’s reforms to remedy medical corruption from pharmaceutical firms
por: Shi, Jianwei, et al.
Publicado: (2018)

Evaluation of financial conflicts of interest and drug statements in the coronavirus disease 2019 clinical practice guideline in Japan
por: Hashimoto, Takanao, et al.
Publicado: (2022)

Conflict of interest disclosure slides at the European Society of Cardiology Congress 2016 in Rome: are they displayed long enough to assess their content? A cross-sectional study
por: van Lieshout, Christianne T, et al.
Publicado: (2018)

Are Pharmaceutical Company Payments Incentivising Malpractice in Japanese Physicians?
por: Kobashi, Yurie, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_pl1hn2aq0uf0ikpsjo4hpv7c99